RG
AMED

Renaissance Group’s Amedisys AMED Stock Holding History

Renaissance Group’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,538
Closed -$713K – 272
2022
Q4 		$713K Sell
8,538
-190
-2% -$17.1K 0.04% 218
2022
Q3 		$845K Buy
8,728
+285
+3% +$34K 0.05% 208
2022
Q2 		$888K Buy
8,443
+421
+5% +$53.8K 0.05% 205
2022
Q1 		$1.38M Buy
8,022
+390
+5% +$58.3K 0.06% 141
2021
Q4 		$1.24M Buy
7,632
+332
+5% +$53.4K 0.05% 155
2021
Q3 		$1.09M Buy
7,300
+3,106
+74% +$646K 0.05% 160
2021
Q2 		$1.03M Buy
4,194
+439
+12% +$115K 0.04% 166
2021
Q1 		$994K Buy
3,755
+180
+5% +$50.8K 0.04% 166
2020
Q4 		$1.05M Buy
3,575
+17
+0.5% +$4.36K 0.05% 139
2020
Q3 		$841K Sell
3,558
-1,010
-22% -$230K 0.04% 135
2020
Q2 		$907K Sell
4,568
-42
-0.9% -$7.83K 0.04% 133
2020
Q1 		$846K Buy
4,610
+254
+6% +$45.2K 0.05% 119
2019
Q4 		$727K Buy
4,356
+378
+10% +$56.2K 0.03% 194
2019
Q3 		$521K Buy
3,978
+41
+1% +$5.34K 0.02% 192
2019
Q2 		$478K Buy
3,937
+40
+1% +$4.75K 0.02% 212
2019
Q1 		$480K Buy
+3,897
New +$489K 0.02% 211

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Renaissance Group's AMED Position: Q1 2023 in Review

Renaissance Group sold out of Amedisys (AMED) in Q1 2023, closing a stake of 8,538 shares — an estimated $713K sold.

Renaissance Group first reported a position in AMED in Q1 2019 and held it in 16 quarters. The position peaked at $1.38M in Q1 2022. 281 funds tracked by Wall St. Rank hold AMED as of Q1 2023.

  • Renaissance Group reported no remaining Amedisys position as of Q1 2023 after selling out during the quarter.
  • Renaissance Group sold 8,538 Amedisys shares in Q1 2023, an estimated $713K.
  • Renaissance Group first reported a position in Amedisys in Q1 2019 and held it in 16 quarters.
  • Renaissance Group's Amedisys position peaked at $1.38M in Q1 2022.
  • 281 funds tracked by Wall St. Rank held Amedisys as of Q1 2023.

Based on Renaissance Group's 13F filing for Q1 2023, filed 12 May 2023.